February 4, 2021
Via: MedPageTodayCombination endocrine therapy reduced estradiol to nearly undetectable levels in men with hormone receptor (HR)-positive breast cancer, though quality of life and sexual function appeared to suffer, a phase II study in Germany showed. In the randomized MALE trial of […]
June 3, 2019
Via: The Medical NewsIn an international, randomized, phase III clinical trial, researchers added an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) to standard endocrine therapy for women with advanced HR-positive/HER2-negative breast cancer. The researchers report that adding the CDK inhibitor significantly increased […]
March 28, 2024
Copyright © 2024. All rights reserved
